TLSI TriSalus Life Sciences, Inc.
USHealthcareAs of 2026-07-08 16:00
Why TLSI matters now
TriSalus Life Sciences, Inc. (TLSI) is a US stock in Healthcare. The latest InvestLog snapshot shows $3.68 with -9.58% on the session and $139.5M in market capitalization; recent performance reads 1-month +29.52% and YTD -41.55%.
The latest financial table shown here is Q1 2026, with revenue of $8.9M, net income of $1.5M, and EPS of $0.03. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -13.1%.
The latest indexable market news headline is "INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc. - TLSI" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $8.00; recent insider activity includes Marshak Richard filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
16.42
P/S
3.45
EV/EBITDA
-6.33
DCF Value
$-126.81
FCF Yield
-13.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
85.1%
Operating Margin
-62.4%
Net Margin
-60.9%
ROE
162.6%
ROA
-38.5%
ROIC
-47.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $8.9M | $1.5M | $0.03 |
| Q4 2025 | $13.2M | $-9.8M | $-0.21 |
| FY 2025 | $45.2M | $-39.2M | $-1.84 |
| Q3 2025 | $11.6M | $-10.8M | $-0.96 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$8.00
Target (Median)
$8.00
Target Range
$8.00 - $8.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Devices
Country
US
Exchange
—
Beta
0.49
TriSalus Life Sciences, Inc. is an immunotherapy firm dedicated to the research, development, and market introduction of treatments that leverage the body's immune system, primarily targeting liver and pancreatic cancers. The company's product portfolio includes the TriNav Infusion System, designed for hepatic arterial infusion to treat liver tumors, and the Pancreatic Retrograde Venous Infusion System, which addresses pancreatic tumors. Additionally, TriSalus is advancing SD-101, an investigational immunotherapeutic that incorporates pressure-enabled drug delivery technology. This experimental therapy is currently being explored for its application in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company's operations are headquartered in Westminster, Colorado.